Xeris Biopharma Holdings, Inc. $XERS Shares Sold by Pallas Capital Advisors LLC

Pallas Capital Advisors LLC lowered its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 28.3% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 11,005 shares of the company’s stock after selling 4,338 shares during the quarter. Pallas Capital Advisors LLC’s holdings in Xeris Biopharma were worth $51,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in XERS. Nuveen LLC acquired a new position in shares of Xeris Biopharma in the 1st quarter valued at about $12,240,000. Parkman Healthcare Partners LLC lifted its holdings in shares of Xeris Biopharma by 207.8% in the 1st quarter. Parkman Healthcare Partners LLC now owns 1,780,454 shares of the company’s stock valued at $9,775,000 after buying an additional 1,201,943 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Xeris Biopharma by 75.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after buying an additional 1,199,435 shares during the period. Invesco Ltd. lifted its holdings in shares of Xeris Biopharma by 1,387.8% in the 1st quarter. Invesco Ltd. now owns 1,026,838 shares of the company’s stock valued at $5,637,000 after buying an additional 957,822 shares during the period. Finally, Driehaus Capital Management LLC lifted its holdings in shares of Xeris Biopharma by 137.6% in the 1st quarter. Driehaus Capital Management LLC now owns 1,411,540 shares of the company’s stock valued at $7,749,000 after buying an additional 817,525 shares during the period. Institutional investors and hedge funds own 42.75% of the company’s stock.

Insiders Place Their Bets

In other news, Director Dawn Halkuff sold 42,500 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $7.28, for a total transaction of $309,400.00. Following the completion of the transaction, the director directly owned 115,000 shares in the company, valued at $837,200. This trade represents a 26.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director John Johnson sold 107,500 shares of the firm’s stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $7.32, for a total value of $786,900.00. Following the transaction, the director owned 833,483 shares of the company’s stock, valued at approximately $6,101,095.56. This represents a 11.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 207,732 shares of company stock valued at $1,550,437. 4.56% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on XERS. Wall Street Zen cut Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a report on Friday, September 5th. Leerink Partners boosted their price objective on Xeris Biopharma from $7.00 to $9.00 and gave the company an “outperform” rating in a report on Tuesday, August 19th. Finally, HC Wainwright initiated coverage on Xeris Biopharma in a report on Tuesday, August 12th. They issued a “buy” rating and a $10.00 price target for the company. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.08.

Xeris Biopharma Stock Performance

Shares of Xeris Biopharma stock opened at $7.91 on Wednesday. The firm has a market capitalization of $1.28 billion, a price-to-earnings ratio of -37.66 and a beta of 0.13. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $2.69 and a fifty-two week high of $8.35. The stock has a 50 day moving average of $6.85 and a 200 day moving average of $5.47.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.02. The business had revenue of $67.71 million during the quarter, compared to analysts’ expectations of $64.58 million. Analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.